A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults

This publication has 45 references indexed in Scilit:

• Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40
  The Journal of Clinical Psychiatry, 2012
• A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*
  International Journal of Neuropsychopharmacology, 2012
• A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
  International Journal of Neuropsychopharmacology, 2011
• Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
  The Journal of Clinical Psychiatry, 2011
• Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
  Journal of Medicinal Chemistry, 2011
• Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study
  International Journal of Neuropsychopharmacology, 2011
• Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
  International Clinical Psychopharmacology, 2009
• Flat Dose-Response Curves for Efficacy: What Do They Mean to the Clinician?
  Journal of Psychiatric Practice, 2008
• Measuring inconsistency in meta-analyses
  BMJ, 2003
• A New Depression Scale Designed to be Sensitive to Change
  The British Journal of Psychiatry, 1979